Company Overview of Watson Laboratories, Inc.
Watson Laboratories, Inc. manufactures pharmaceutical drugs. The company was incorporated in 1992 and is based in Corona, California. Watson Laboratories, Inc. operates as a subsidiary of Allergan plc.
132 Business Center Drive
Corona, CA 92880-1724
Founded in 1992
Key Executives for Watson Laboratories, Inc.
Watson Laboratories, Inc. does not have any Key Executives recorded.
Watson Laboratories, Inc. Key Developments
The State of California Sues Watson Laboratories, Allergan Finance LLC, Activis Inc. and Allergan plc
Feb 3 17
The state of California has brought a lawsuit against units of Allergan plc and Teva Pharmaceutical Industries Ltd. Inc. alleging the pharmaceutical companies obstructed generic competition regarding the sale of Lidoderm. The unsealed, partially redacted, lawsuit filed Feb. 3 in federal court in San Francisco, claims that Allergan signed an agreement with Endo Pharmaceuticals Inc. promising that the company would not face any generic competition for Lidoderm from units of Allergan from May 2012 through September 2013 and in turn that Allergan would not face any competition from Endo until May 2014. The lawsuit termed the deal a 'pay-for-delay agreement'. The lawsuit names Watson Laboratories, now a subsidiary of Teva; Allergan Finance LLC, also known as Watson Pharmaceuticals Inc.; Activis Inc.; and Allergan plc. The action claims that as a result of the agreement, consumers had to pay hundreds of millions of dollars in surpa-competitive prices for prescriptions of Lidoderm as well as AB-rate generic equivalents from May 2012 for two years. The agreement with Allergan was critical for Endo since Lidoderm generated $825 million in revenues for Endo in 2011, and the entry of a generic competitor could have hit Endo hard. Allergan was set to introduce a generic version of the drug in 2012, but the signing of the agreement kept the drug on the sidelines, ensuring higher prices for Lidoderm. The 10-count legal action asks the court to judge the agreement to be a violation of the Sherman Act, constituting a restraint of trade, a conspiracy to monopolize trade, and that those ill-gotten gains be disgorged, and that the defendant companies pay $2,500 for each violation proven at trial.
US Federal Trade Commission Announces Lawsuit Filed against Watson and Allergan
Jan 23 17
Endo International and the US Federal Trade Commission resolved an FTC complaint that claimed Endo violated antitrust laws by using so-called pay-for-delay settlements that would block access to lower-cost generic versions of its Lidoderm and Opana ER drugs. In relation, the FTC refiled charges against Watson Laboratories and its former parent, Allergan for illegally blocking a lower-cost generic version of Lidoderm when it entered into a pay-for-delay agreement with Endo.
Endo International Plc and Allergan Plc Units get Dragged to Court by US Federal Trade Commission Over Stifling Generic Competition
Apr 1 16
Endo International Plc and Allergan Plc announced that they have become the targets of a lawsuit launched by the US Federal Trade Commission (FTC), which alleges that subsidiaries of the two companies struck illegal agreements to delay the market entry of generic Opana ER and Lidoderm versions. The FTC filed its complaint on March 31, 2016, naming as guilty parties Endo Pharmaceuticals Inc, Allergan and its unit Watson Laboratories Inc, Impax Laboratories Inc, Teikoku Seiyaku Co Ltd. and Teikoku Pharma USA Inc. The two drugs at the centre of the complaint are Endo-branded products, Opana being an extended-release opioid painkiller and Lidoderm being a topical patch for relieving post-herpetic neuralgia pain. Impax and Watson were the first companies to seek approval from the US Food and Drug Administration for generic versions of these drugs. According to the FTC, Endo paid them to postpone the launch of the generic products and these so-called pay-for-delay settlements violate US antitrust laws. The complaint alleges that Endo and Impax entered into an illegal agreement in 2010, with the latter receiving more than USD 112 million (EUR 98.2 million) to hold off the launch of its Opana ER equivalent until January 2013. The amount included USD 10 million received by Impax as part of a development and co-promotion deal struck within that period. The illegal agreement with Watson over Lidoderm was signed in May 2012 and involved Endo partners Teikoku Seiyaku Co Ltd. and Teikoku Pharma USA Inc. as well. The FTC did not provide a specific figure for the payment received by Watson, saying only it amounted to hundreds of millions of dollars and the company pocketed a similar amount when it finally launched its generic version of the drug. This was the result of Endo's consent to refrain from selling an authorised Lidoderm generic version for seven and a half months, thus leaving Watson without any competition for a while.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|